Deltex Medical Group 2021 revenue plummeted due to pandemic

By Anthony O. Goriainoff

Deltex Medical Group PLC said on Tuesday that revenues for 2021 had fallen due to the effects of the pandemic and the significant reduction in elective surgeries globally.

The UK maker of blood flow monitoring technology – hemodynamics – said revenue was £ 2.3million ($ 3.1million) compared to £ 2.4million for 2020.

The company said the backlog of elective surgical cases continues to build around the world and the board sees this as a key opportunity.

The company said its business experienced disruption associated with the pandemic for all of 2021, unlike 2020, when first quarter business was not so badly affected. He added that although its direct operations in the US and UK have not yet returned to pre-pandemic levels, the performance of its international division has improved significantly over the year.

“As the world begins to learn to live with Covid-19 and we bring our new, easy-to-use hemodynamic monitoring technology to market with applications beyond elective surgery, we believe our business will grow in 2022. The company said.

Write to Anthony O. Goriainoff at [email protected]

Comments are closed.